Maria Domenica Cappellini

Maria Domenica Cappellini

orcid

Research Focus & Metrics

Academic Career Length

53Years (1974-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in The Lancet
Verified
Journal Article
Closed access
MCMaria Domenica Cappellini
Maria Domenica Cappellini
GFG Fiorelli
G Fiorelli

1 January 2018 in The Lancet
Verified
Journal Article
Closed access
Ali TaherAli Taher
Ali Taher
DWDavid J Weatherall
David J Weatherall
MCMaria Domenica Cappellini
Maria Domenica Cappellini

1 May 2006 in Blood
Verified
Journal Article
Open access
PDF file
MCMaria Domenica Cappellini
Maria Domenica Cappellini
Deferasirox (ICL670) is a once-daily oral iron chelator developed for the treatment of chronic iron overload from blood transfusions. A comparative phase 3 trial was conducted to demonstrate the efficacy of deferasirox in regularly transfused patients with β-thalassemia aged 2 years or older. Patients were randomized and received treatment with deferasirox (n = 296) or deferoxamine (n = 290), with dosing of each according to baseline liver iron concentration (LIC). The primary endpoint was maintenance or reduction of LIC; secondary endpoints included safety and tolerability, change in serum ferritin level, and net body iron balance. In both arms, patients with LIC values of 7 mg Fe/g dry weight (dw) or higher had significant and similar dose-dependent reductions in LIC and serum ferritin, and effects on net body iron balance. However, the primary endpoint was not met in the overall population, possibly due to the fact that proportionally lower doses of deferasirox relative to deferoxamine were administered to patients with LIC values less than 7 mg Fe/g dw. The most common adverse events included rash, gastrointestinal disturbances, and mild nonprogressive increases in serum creatinine. No agranulocytosis, arthropathy, or growth failure was associated with deferasirox administration. Deferasirox is a promising once-daily oral therapy for the treatment of transfusional iron overload.

1 October 2015 in Seminars in Hematology
Verified
Journal Article
Closed access
MCMaria Domenica Cappellini
Maria Domenica Cappellini
IMIrene Motta
Irene Motta

30 October 2019 in Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
MCMaria Domenica Cappellini
Maria Domenica Cappellini
Khaled MusallamKhaled Musallam
Khaled Musallam
ATAli T. Taher
Ali T. Taher
Iron deficiency anaemia is a global health concern affecting children, women and the elderly, whilst also being a common comorbidity in multiple medical conditions. The aetiology is variable and attributed to several risk factors decreasing iron intake and absorption or increasing demand and loss, with multiple aetiologies often coexisting in an individual patient. Although presenting symptoms may be nonspecific, there is emerging evidence on the detrimental effects of iron deficiency anaemia on clinical outcomes across several medical conditions. Increased awareness about the consequences and prevalence of iron deficiency anaemia can aid early detection and management. Diagnosis can be easily made by measurement of haemoglobin and serum ferritin levels, whilst in chronic inflammatory conditions, diagnosis may be more challenging and necessitates consideration of higher serum ferritin thresholds and evaluation of transferrin saturation. Oral and intravenous formulations of iron supplementation are available, and several patient and disease‐related factors need to be considered before management decisions are made. This review provides recent updates and guidance on the diagnosis and management of iron deficiency anaemia in multiple clinical settings.

13 June 2017 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
MCMaria Domenica Cappellini
Maria Domenica Cappellini
JCJosep Comin‐Colet
Josep Comin‐Colet
AFAngel de Francisco
Angel de Francisco
ADAxel Dignass
Axel Dignass
WDWolfram Doehner
Wolfram Doehner
OGon behalf of the IRON CORE Group
on behalf of the IRON CORE Group
Iron deficiency, even in the absence of anemia, can be debilitating, and exacerbate any underlying chronic disease, leading to increased morbidity and mortality. Iron deficiency is frequently concomitant with chronic inflammatory disease; however, iron deficiency treatment is often overlooked, partially due to the heterogeneity among clinical practice guidelines. In the absence of consistent guidance across chronic heart failure, chronic kidney disease and inflammatory bowel disease, we provide practical recommendations for iron deficiency to treating physicians: definition, diagnosis, and disease‐specific diagnostic algorithms. These recommendations should facilitate appropriate diagnosis and treatment of iron deficiency to improve quality of life and clinical outcomes.